The Pivot To solve this biological barrier, advanced manufacturing has shifted toward phospholipid encapsulation technology
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
This advanced peptide formula also contributes to nervous system resilience and recovery from physical stress
Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation
USA-made and manufactured for reliable research quality
All content on Ground Truthsits newsletters, analyses, and podcasts, are free, open-access